Damora Therapeutics (DMRA) Other Working Capital Changes (2019 - 2026)
Damora Therapeutics' (DMRA) quarterly Other Working Capital Changes came in at -$290000.0 in Q1 2026, down 189.78% YoY from $323000.0 in Q1 2025, and down 5700.0% on a QoQ basis from -$5000.0 in Q4 2025.
Damora Therapeutics (DMRA) Other Working Capital Changes (2019 - 2026) Analysis & Trends
Damora Therapeutics (DMRA) has 8 years of Other Working Capital Changes data on file, last reported at -$290000.0 in Q1 2026.
- Quarterly Other Working Capital Changes fell 1700.0% year-over-year to -$54000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$66000.0 (changed N/A YoY) and the FY2025 annual result came in at -$15000.0, down 134.88% from the prior year.
- Other Working Capital Changes fell to -$54000.0 in Q1 2026, from -$21000.0 in the prior quarter.
- In the past five years, Other Working Capital Changes ranged from a high of $8000.0 in Q2 2025 to a low of -$54000.0 in Q1 2026.
- A 5-year average of -$94294.1 and a median of -$92000.0 in 2024 frame the typical range for Other Working Capital Changes.
- Annual changes were most pronounced in 2022 — Other Working Capital Changes tumbled 647.89% — and 2024, when it surged 820.28%.
- Tracing DMRA's Other Working Capital Changes over 2 years: stood at -$21000.0 in 2025, then slumped by 157.14% to -$54000.0 in 2026.
- The last three Other Working Capital Changes figures came in at -$54000.0 (Q1 2026), -$21000.0 (Q4 2025), and $1000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Damora Therapeutics | 1.92 Bn | 1.38 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 564,000.00 |
| Jun 30, 2026 | 564,000.00 |
| Jun 30, 2026 | 564,000.00 |
| Mar 31, 2026 | -290,000.00 |
| Mar 31, 2026 | -290,000.00 |
| Mar 31, 2026 | -290,000.00 |
| Dec 31, 2025 | -5,000.00 |
| Dec 31, 2025 | -5,000.00 |
| Dec 31, 2025 | -5,000.00 |
| Sep 30, 2025 | -5,000.00 |
| Sep 30, 2025 | -5,000.00 |
| Sep 30, 2025 | -5,000.00 |
| Jun 30, 2025 | -333,000.00 |
| Jun 30, 2025 | -333,000.00 |
| Jun 30, 2025 | -333,000.00 |
| Mar 31, 2025 | 323,000.00 |
| Mar 31, 2025 | 323,000.00 |
| Mar 31, 2025 | 323,000.00 |
| Dec 31, 2024 | 1.95 Mn |
| Dec 31, 2024 | 1.95 Mn |